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Neurodevelopmental problems (NPs) are more common in males, whereas anxiety and depres-
sion are more common in females. Rare copy number variants (CNVs) have been implicated in
neurodevelopmental disorders. The aim of this study was to characterize the relationship
between rare CNVs with NPs, anxiety, and depression in a childhood population sample, as well
as to examine sex-specific effects. We analyzed a sample of N = 12,982 children, of whom 5.3%
had narrowly defined NPs (clinically diagnosed), 20.9% had broadly defined NPs (based on vali-
dated screening measures, but no diagnosis), and 3.0% had clinically diagnosed anxiety or
depression. Rare (<1% frequency) CNVs were categorized by size (100–500 kb or > 500 kb),
type, and putative relevance to NPs. We tested for association of CNV categories with out-
comes and examined sex-specific effects. Medium deletions (OR[CI] = 1.18[1.05–1.33],
p = .0053) and large duplications (OR[CI] = 1.45[1.19–1.75], p = .00017) were associated with
broadly defined NPs. Large deletions (OR[CI] = 1.85[1.14–3.01], p = .013) were associated with
narrowly defined NPs. There were no significant sex differences in CNV burden in individuals
with NPs. Although CNVs were not associated with anxiety/depression in the whole sample, in
individuals diagnosed with these disorders, females were more likely to have large CNVs (OR
[CI] = 3.75[1.45–9.68], p = .0064). Rare CNVs are associated with both narrowly and broadly
defined NPs in a general population sample of children. Our results also suggest that large, rare
CNVs may show sex-specific phenotypic effects.
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1 | INTRODUCTION
Neurodevelopmental problems (NPs) are psychiatric phenotypes that
are characterized by childhood onset, high levels of comorbidity with
other NPs, and other psychiatric conditions, and being more com-
monly diagnosed in males than females (Thapar, Cooper, & Rutter,
2017). Common diagnoses of NPs include attention-deficit/hyperac-
tivity disorder (ADHD), autism spectrum disorder (ASD), developmen-
tal coordination disorder (DCD), tic disorders, and intellectual
disability (ID) (also referred to as learning difficulties). NPs are highly
heritable, with a complex genetic architecture according to emerging
genetic studies (de la Torre-Ubieta, Won, Stein, & Geschwind, 2016;
Faraone et al., 2015; O'Rourke, Scharf, Yu, & Pauls, 2009). Rare
genetic variants, such as copy number variants (CNVs) and protein-
truncating variants have been implicated in clinically diagnosed
ASD, ID, ADHD, DCD, and Tourette's syndrome (De Rubeis et al.,
2014; Ganna et al., 2018; Girirajan et al., 2011; Huang et al., 2017;
Mosca et al., 2016; Sanders et al., 2015; Williams et al., 2012). The
contribution of rare variants to risk of anxiety and depression diag-
noses in children has not been well characterized, with one recent
population study finding no evidence of association (Guyatt
et al., 2018).
Although genetic studies of NPs have tended to focus on categor-
ically defined clinical disorders, evidence is emerging to suggest that
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these disorders reflect a quantitative extreme of continuously distrib-
uted traits in the general population. Twin studies suggest that ADHD,
ASD, and mild ID share genetic risks with related traits in the popula-
tion (Martin, Taylor, & Lichtenstein, 2017). Genome-wide studies fur-
ther demonstrate that common variants are shared to a degree
between disorders and traits related to ADHD, ASD, and Tourette's
syndrome (Darrow et al., 2017; Demontis et al., 2017; Robinson
et al., 2016).
Evidence for shared rare variants across psychiatric disorders
and related population traits or subthreshold psychiatric problems is
also emerging. In a study of autism simplex families, adaptive and
social-communication difficulties in ASD probands and their unaf-
fected siblings were associated with very rare de novo protein-
truncating variants, with no qualitative distinction between pro-
bands and siblings in this association (Robinson et al., 2016). A few
studies have examined the manifestation of CNVs in adults in the
general population, focusing on “neuropsychiatric” CNVs (i.e., loci
robustly implicated in psychiatric disorders). These neuropsychiatric
CNVs were associated with depression, lower scores on the General
Assessment of Function scale, a history of reading and mathematical
learning difficulties, lower cognitive abilities, and educational attain-
ment in adults in the general population (Kendall et al., 2016;
Männik et al., 2015; Stefansson et al., 2014). It appears that the
same rare CNV loci are not only associated with multiple clinically
diagnosed neuropsychiatric disorders (e.g., ASD, ID, schizophrenia,
and ADHD [Girirajan et al., 2012; Marshall et al., 2016; Williams
et al., 2012]) but also with neuropsychiatric and cognitive outcomes
in adults in the general population (Kendall et al., 2016; Männik
et al., 2015; Stefansson et al., 2014). The impact of CNVs on more
broadly defined NPs in nonclinical childhood population samples
has not been thoroughly examined. One recent population study of
British children found associations between CNVs and cognitive
measures (e.g., IQ) and ASD diagnoses but not anxiety or depression
diagnoses or quantitative psychiatric traits of ADHD, ASD, or psy-
chotic experiences (Guyatt et al., 2018). Further studies are needed
to more fully characterize the impact of CNVs on childhood psychi-
atric problems.
One prominent characteristic of NPs is that they are more com-
monly diagnosed in males than females (Thapar et al., 2017). Popula-
tion studies of childhood NPs also suggest that males score higher on
measures of NPs than females (Larsson, Anckarsater, Råstam, Chang, &
Lichtenstein, 2011; Lingam et al., 2010; Robinson, Lichtenstein,
Anckarsäter, Happé, & Ronald, 2013). Although the reasons for this
are still unclear, a few possible explanations have been proposed.
First, it has been suggested that females are protected (e.g., by hor-
monal differences) from manifesting NPs and require a higher burden
of risk to develop NPs. Evidence from several family studies seems to
support this hypothesis (Beitchman, Hood, & Inglis, 1992; Martin,
Walters, et al., 2018; Rhee & Waldman, 2004; Robinson et al., 2013;
Smalley et al., 2000; Szatmari et al., 2012; Taylor et al., 2016), albeit
other studies are inconsistent (Chen et al., 2017; Conti-Ramsden,
Falcaro, Simkin, & Pickles, 2007; Faraone, 2000; Goin-Kochel, Abbac-
chi, & Constantino, 2007). Evidence from common variant analyses is
also mixed, with the largest studies not finding differences in poly-
genic burden between males and females with ADHD and ASD
(Hamshere et al., 2013; Martin, Hamshere, Stergiakouli, O'Donovan, &
Thapar, 2014; Martin, Walters, et al., 2018; Mitra et al., 2016; Weiner
et al., 2017). Conversely, females diagnosed with ASD or developmen-
tal delay appear to have an increased burden of rare disruptive CNVs
and deleterious single-nucleotide mutations compared with affected
males (Gilman et al., 2011; Iossifov et al., 2012; Jacquemont et al.,
2014; Levy et al., 2011; Neale et al., 2012; Pinto et al., 2014), though
others have not found this effect for ultra-rare protein-truncating vari-
ants (Ganna et al., 2018). It is unknown whether rare CNVs are
enriched in females compared to males in individuals affected with a
broader range of NPs (e.g., ADHD and tic problems) in the general
population.
Another possibility is that referral and diagnostic biases or sex-
specific manifestation of risk result in fewer females being diagnosed
with NPs (Loomes, Hull, & Mandy, 2017; Quinn & Madhoo, 2014). It
has been suggested that childhood psychiatric problems in females
either manifest differently than in males or are interpreted differently
by parents and teachers, for example, as anxiety or depression, instead
of ADHD or ASD (Hull & Mandy, 2017; Quinn & Madhoo, 2014). If
either of these are the case, one might expect that genetic risk factors
relevant to NPs, such as rare CNVs, would be more strongly associ-
ated with such other psychiatric problems in females. This possibility
has yet to be examined.
In this study, we first set out to test whether rare CNVs are
associated with NPs (i.e., ADHD, ASD, motor problems, learning
difficulties, and tic problems) and anxiety/depression in a popula-
tion sample of children. Linkage with Swedish National Patient Reg-
isters and available study-specific questionnaires allowed us to use
both narrow (i.e., clinical diagnosis) and broad (i.e., screening mea-
sure) definitions of NPs, to distinguish between clinically recog-
nized problems and subthreshold population phenotypic variation.
Second, we tested whether there are any sex differences in CNV
burden in the context of NPs or anxiety/depression in the
population.
2 | METHOD
2.1 | Sample description
The Child and Adolescent Twin Study in Sweden (CATSS) is a popula-
tion study of twin children born in Sweden since July 1992
(Anckarsäter et al., 2012). The study started in 2004 and since then
has been the method of inviting twins into the Swedish Twin Registry
(Magnusson et al., 2013). The CATSS cohort is being recruited when
twins turn 9-years old, but initially, 12-year-old twins were also
recruited. Parents gave informed consent for study participation on
behalf of their children. The study was approved by the Regional Ethi-
cal Review Board in Stockholm and Karolinska Institutet Ethical
Review Board.
2.2 | Phenotypic measures
Information on five specific NPs (ADHD, ASD, motor problems, learn-
ing difficulties, and tic problems) was obtained from two sources: life-
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time registry-based clinical diagnoses and screening via parental
report at age 9 or 12 years old. Diagnoses for these NPs, as well as
life-time anxiety and depression, were obtained through linkage with
the National Patient Register (NPR) in Sweden, using each individual's
personal identification number. This NPR linkage contains information
on all inpatient psychiatric care from 1987 to 2014 and outpatient
consultations with specialists from 2001 to 2014. It includes best-
estimate specialist diagnoses according to International Classification
of Diseases version 10 (ICD-10) codes (WHO, 1993). Individuals were
dichotomized based on presence or absence of each of the diagnoses.
See Table 1 for a list of ICD codes and numbers of affected
individuals.
Study individuals were also screened for NPs using the Autism-
Tics, ADHD, and Other Comorbidities inventory (A-TAC) (Hansson
et al., 2005) administered to parents over the telephone when chil-
dren were aged 9 or 12 years. This measure has been reported to
have good to excellent sensitivity and specificity for predicting clinical
diagnoses, using validated clinical cut-offs (Larson et al., 2013). These
validated cut-offs were used to dichotomize children for each of the
five NPs. Because ADHD, ASD, motor problems, learning difficulties,
and tic problems show a high degree of comorbidity (Larson et al.,
2013) (with substantial overlap also seen in CATSS, both for clinical
ICD diagnoses and validated cut-offs), we derived two summary mea-
sures based on meeting criteria for one or more of these NPs. Individ-
uals receiving one or more ICD diagnosis of NPs were classed as
having “narrowly defined NPs,” whereas individuals meeting any
screening cut-off based on the A-TAC, but not receiving any of the
clinical diagnoses, were classed as having “broadly defined NPs.”
Presence of NPs using these two definitions were the primary out-
comes in analyses. Individuals who did not meet criteria for either
broadly or narrowly defined NPs were considered as the unaffected/
control group, for all analyses. See Table 1 for details.
Separate variables were also derived for each of the five specific
NPs, categorized using a combined definition of either broadly or nar-
rowly defined NPs, as a result of limited power (see Table 1). It was
possible for individuals to be categorized for more than one specific
NP. A continuous measure of total NPs was derived by summing
together the A-TAC scales for all five NPs for each individual (range of
scores: 0–43).
2.3 | CNV calling and processing
DNA samples (from saliva) have been collected since 2008 from the
participants after they are initially recruited to the study. DNA was
extracted using the Chemagic STAR instrument from Hamilton Robot-
ics and Puregene extraction kits. Samples were genotyped using the
Illumina Infinium PsychArray-24 BeadChip. For details of sample pro-
cessing and standard genotype quality control (QC), see Brikell
et al. (2018) and Supporting Information Text. For details of CNV call-
ing and QC, see Supporting Information Text, and for an overview,
see Supporting Information Figure S1. CNVs were called using the
standard PennCNV (Wang et al., 2007) protocol. Strict CNV- and
sample-level QC was performed, following the protocol developed by
the Psychiatric Genomics Consortium (Marshall et al., 2016). After all
QC, the sample size for analysis consisted of N = 12,982 individuals,
including N = 2,445 monozygotic and N = 3,554 dizygotic twin pairs.
TABLE 1 Phenotype descriptions
Phenotype
Narrowly defined psychiatric disorders Broadly defined NPsa
Specific NPsb
ICD diagnostic codes
N (%)
affected
Description of A-TAC
measure
N (%)
affected
Overall N (%)
affected
ADHD ADHD/hyperkinetic disorder (F90) 430 (3.3%) 19 items; screening
cut-off: ≥6
931 (7.2%) 1,361 (12.3%)
ASD Autism (F84) 170 (1.3%) 17 items; screening
cut-off: ≥4.5
273 (2.1%) 443 (4.4%)
Motor
problems
Motor disorders (F82) 22 (0.2%) 1 item; screening cut-off:
≥0.5
864 (6.7%) 886 (8.4%)
Tic disorders Tic disorders (F95) 42 (0.3%) 3 items; screening cut-off:
≥1.5
384 (3.0%) 426 (4.2%)
Learning
difficulties
ID (F70-F79), language disorders (F80), scholastic
disorders (F81)
233 (1.8%) 3 items; screening cut-off:
≥1
1,641
(12.6%)
1,874 (16.2%)
Any NPs Any of the above 689 (5.3%) Any of the above 2,569
(20.9%)
3,258 (25.1%)
Anxiety Social anxiety & phobias (F40), generalized anxiety
and panic disorders (F41), separation anxiety
and other childhood-onset anxiety disorders
(F93)
256 (2.0%)
Depression Single and recurrent major depressive disorders
(F32-F34)
220 (1.7%)
Anxiety/
depression
Either of the above 383 (3.0%)
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder; A-TAC, Autism-Tics, ADHD, and Other Comorbidities inventory; ICD,
International Classification of Diseases; ID: intellectual disability; NPs, neurodevelopmental problems.
Note. Diagnoses for each phenotype were collapsed into binary variables.
a Excludes all individuals diagnosed with any narrowly defined NPs.
b Combined definition of either broadly or narrowly defined NPs for each of the specific phenotypes. Individuals may be affected with multiple spe-
cific NPs.
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2.4 | CNV category definitions
CNV categories were defined based on size (all: >100 kb; medium:
100–500 kb; large: >500 kb), type (deletion or duplication), and pre-
sumed relevance to NPs (relevant CNV or other CNV). CNVs relevant
to NPs were defined as those that either overlapped at least 50% with
any of 69 genomic loci that have previously been implicated in ASD,
ID, and/or schizophrenia (Coe et al., 2014; Marshall et al., 2016;
Sanders et al., 2015) or with any gene within a set of 3,219 highly
evolutionarily constrained genes that are intolerant to mutations (Lek
et al., 2016). Further details about the definitions of these genomic
regions can be found in the Supporting Information Text. CNVs that
overlapped with these loci are referred to as neuropsychiatric disor-
der/evolutionarily constrained CNVs or “ND/EC CNVs” for short and
CNVs that did not overlap are referred to as “other CNVs.” For all cat-
egories of CNVs, the number of CNV segments was categorized as
“absent” if no CNV call had been made for an individual within the
category or “present” if at least one called CNV met the criteria for
that category.
2.5 | Data analyses
For the primary analysis, we examined the overall association of all
CNVs passing QC, with narrowly and broadly defined NPs, as well as
with clinically defined anxiety/depression.
Several secondary tests were then performed to further examine
the relationship between CNVs and these neuropsychiatric outcomes.
First, CNVs were categorized by size and type to test the association
of different CNV categories with each outcome. To determine
whether the impact of rare CNVs differed in children with narrowly or
broadly defined NPs, we compared the burden of each CNV category
in relation to these outcomes. Next, we examined whether CNVs
were associated with a continuous measure of NPs. We also exam-
ined whether significant associations for broad or narrow NPs were
driven by specific NPs. Finally, we compared carriers of at least one
ND/EC-CNV and carriers of other CNVs to controls and to each
other, to further characterize the origin of significant associations.
Several specific analyses were performed to investigate hypothe-
sized sex-specific CNV effects. First, we tested for an overall differ-
ence in CNV burden by sex in the whole sample. To test the
hypothesis that females with NPs are carriers of a higher burden of
risk variants as compared to affected males, we compared CNV bur-
den by sex in individuals with NPs. To test the alternative hypothesis
that genetic risk factors relevant to NPs are more likely to be associ-
ated with anxiety/depression in females than in males, we compared
CNV burden by sex in individuals with any anxiety or depression diag-
nosis. We also tested the impact of comorbid clinically diagnosed NPs
on this relationship by adjusting for the continuous measure of NPs.
For all sex-specific analyses, males were coded as “0” and females
as “1.”
All analyses were performed using logistic or linear generalized
estimating equations (with the package drgee [Zetterqvist & Sjölander,
2015] in R-3.4.1), using family ID to cluster the data to account for
related samples. The following covariates were included for all
analyses: LRR SD, BAF SD, waviness factor, batch, and five principal
components. Results were evaluated using an alpha level of 0.05.
3 | RESULTS
Table 1 shows details of the psychiatric outcomes. There was a strong
association between a child receiving an ICD diagnosis of any NP (nar-
rowly defined NPs) and meeting study screening criteria for any NP
(OR[CI] = 9.66[8.04–11.59], p = 1.2E-130). N = 689 (5.3%) children
had narrowly defined NPs, N = 2,569 children (19.8%) had broadly
defined NPs (based on meeting screening cut-offs but not receiving
clinical diagnoses), and N = 9,724 (74.9%) children were unaffected
by any definition of NPs. N = 383 (3.0%) children had clinically diag-
nosed anxiety and/or depression.
3.1 | Association of CNVs with neuropsychiatric
outcomes
There was an overall association between a child having any rare
(<1% frequency) CNV >100 kb in size and having any broadly defined
NPs (OR[CI] = 1.13[1.03–1.25], p = .014). There were no overall asso-
ciations of presence of any CNVs with narrowly defined NPs (OR
[CI] = 1.09[0.92–1.30], p = .31) or anxiety/depression diagnoses (OR
[CI] = 1.15[0.92–1.42], p = .22).
3.1.1 | Secondary analyses
Associations between CNV categories of different sizes and types
with NPs are shown in Figure 1a (see Supporting Information
Table S1 for exact estimates). These secondary analyses indicated that
medium-sized (100–500 kb) deletions (OR[CI] = 1.18[1.05–1.33],
p = .0053) and large (>500 kb) duplications (OR[CI] = 1.45
[1.19–1.75], p = .00017) drove the observed overall association of
CNVs with broadly defined NPs. Although there was no overall associ-
ation between CNVs and narrowly defined NPs, large deletions did
increase risk for this outcome (OR[CI] = 1.85[1.14–3.01], p = .013).
There were no significant differences in presence of CNVs between
children with narrowly or broadly defined NPs, except for large dele-
tions (OR[CI] = 1.82[1.06–3.11], p = .028), which were more common
in those with narrowly defined NPs (see Supporting Information
Table S2). No CNV category was significantly associated with anxiety/
depression; see Supporting Information Table S3.
CNVs were also associated with the continuous measure of total
NPs (Table 2), with the strongest associations once again observed for
medium deletions (beta[SE] = 0.30[0.11], p = .009) and large duplica-
tions (beta[SE] = 0.42[0.21], p = .046), suggesting that a medium-
sized CNV was associated with an average increase of 0.30 NP symp-
toms, and a large duplication was associated with an average increase
of 0.42 NP symptoms. Excluding individuals with clinically diagnosed
NPs reduced these effects (medium deletions: beta[SE] = 0.26[0.10],
p = .0055; large duplications: beta[SE] = 0.27[0.17], p = .099); see
Table 2.
Next, we examined the association of CNVs with specific NPs
(see Figure 1b and Supporting Information Table S4). Medium dele-
tions were significantly associated with ADHD (OR[CI] = 1.20
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[1.03–1.40], p = .017) and learning difficulties (OR[CI] = 1.24
[1.08–1.42], p = .0017). Large duplications were associated with
ADHD (OR[CI] = 1.53[1.20–1.95], p = .00051), motor problems (OR
[CI] = 1.43[1.08–1.91], p = .013), and learning difficulties (OR[CI] =
1.37[1.10–1.71], p = .0047). Large deletions were also associated
with motor problems (OR[CI] = 1.75[1.12–2.72], p = .013). Although
the effect sizes for the association of CNV classes with ASD and large
duplications with tics were similar to the analyses of ADHD and learn-
ing difficulties, these results did not reach significance (see Supporting
Information Table S4).
When analyses were limited to individuals who are carriers of
ND/EC CNVs (i.e., CNVs likely to be relevant to NPs) as compared
with individuals without any CNVs, the observed effect sizes for large
CNVs increased for both broadly (OR[CI] = 1.60[1.06–2.42], p = .025)
and narrowly defined (OR[CI] = 3.64[2.16–6.13], p = 1.15E-6) NPs
(Supporting Information Table S5). Figure 2 shows the proportion of
NPs in the different CNV carrier groups. Carriers of other (non-ND/
EC) large CNVs also had a higher proportion of broadly defined NPs
as compared with noncarriers (OR[CI] = 1.28[1.06–1.54], p = .010).
This association was nonsignificant for medium-sized CNVs and for
narrowly defined NPs as an outcome (Supporting Information
Table S5). Conversely, carriers of large ND/EC CNVs had an increased
risk of narrowly defined NPs compared to carriers of other large CNVs
(OR[CI] = 3.65[1.83–7.27], p = 2.3E-4); this effect was nonsignificant
when examining medium-sized CNVs or broadly defined NPs
(Supporting Information Table S5).
3.2 | Sex-specific analyses
N = 1,486 (23.0%) males and N = 1,083 (16.6%) females met criteria
for broadly defined NPs, N = 482 (7.5%) males and N = 207 (3.2%)
females met criteria for narrowly defined NPs, and N = 157 (2.4%)
males and N = 226 (3.5%) females met criteria for anxiety/depression;
these sex differences were statistically significant (broad NPs: OR =
0.63[0.57–0.69], p = 7.4E-22; narrow NPs: OR = 0.37[0.31–0.44],
p = 6.6E-27; anxiety/depression: OR = 1.44[1.16–1.79], p = 9.2E-4).
There was no overall difference in presence of CNVs by sex; see
Table 3. There were also no significant sex differences in CNV pres-
ence in children with narrowly or broadly defined NPs. Conversely, in
FIGURE 1 Association between presence of rare CNVs categorized by size (all: >100 kb; medium: 100–500 kb; large: >500 kb) and type (del:
deletion; dup: duplication) with NPs, defined as: (a) broadly defined NPs (i.e., meeting criteria using study screening measures but not receiving
clinical diagnoses) or narrowly defined NPs (i.e., receiving clinical diagnoses in the Swedish register data); and (b) specific NPs, using a combined
definition of children meeting criteria for either broadly or narrowly defined NPs. Note that there is an overlap across the groups with some
children affected with more than one NP. ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; CI, 95% confidence
interval; LD, learning difficulties; OR, odds ratio [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Association of presence of CNVs (categorized by size and type) with a continuous measure of NPs
CNV size CNV type
Full sample (N = 12,982) Excluding those with narrow NPs (N = 12,293)
Beta (SE) p Beta (SE) p
All (>100 kb) All 0.20 (0.09) .0228 0.17 (0.07) .0186
Del 0.31 (0.11) .00559 0.28 (0.09) .00263
Dup 0.08 (0.10) .434 0.06 (0.08) .487
Medium (100–500 kb) All 0.16 (0.09) .0817 0.15 (0.08) .04
Del 0.30 (0.11) .00904 0.26 (0.10) .0055
Dup −0.01 (0.10) .922 0.02 (0.08) .804
Large (>500 kb) All 0.35 (0.18) .0474 0.26 (0.15) .0777
Del 0.14 (0.30) .643 0.24 (0.30) .423
Dup 0.42 (0.21) .0461 0.27 (0.17) .0994
CNVs, copy number variants; Del, deletions; Dup, duplications; NPs: neurodevelopmental problems.
MARTIN ET AL. 5
those who had anxiety or depression diagnoses, females were signifi-
cantly more likely than males to have large CNVs. The estimated
effect size for this association increased when comorbid NPs were
adjusted for, by including the continuous measure of NPs as a covari-
ate in this analysis (Table 3).
4 | DISCUSSION
The results of this study add to the growing body of literature on the
role of CNVs in psychiatric phenotypes. Our results are consistent
with previous clinical studies of NPs, which reported significant
enrichment of rare, deleterious CNVs in individuals with clinically
diagnosed NPs (Girirajan et al., 2011; Huang et al., 2017; Mosca et al.,
2016; Sanders et al., 2015; Williams et al., 2012). In this study, we
extend this knowledge by also implicating rare CNVs in children with
more broadly defined, subthreshold NPs and continuously assessed
traits of broad NPs, which has not been shown before. We found no
association between rare CNVs and clinically diagnosed anxiety and
depression in this childhood sample, in line with a recent childhood
population study (Guyatt et al., 2018), albeit in contrast to a population
study which found an association between neuropsychiatric CNVs and
depression (though not anxiety) in adults (Stefansson et al., 2014).
Although we found no differences in CNV burden by sex in individuals
with NPs, our results suggested that CNVs are enriched in females
diagnosed with depression or anxiety, as compared to diagnosed males.
FIGURE 2 The proportion of broadly and narrowly defined NPs compared across carriers of CNVs that affect neuropsychiatric disorders or
evolutionarily constrained genes (ND/EC CNVs), carriers of other CNVs, and controls who do not carry any CNVs, with CNVs stratified by size.
*p < .05; **p < .01; ***p < .001 [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Associations of CNVs with sex
Sample CNV size CNV presence (%) in females/males OR(CI) p
Whole sample (N = 12,982) All 43.9/44.4 0.99(0.91–1.08) .85
Medium 39.7/40.3 0.99(0.91–1.07) .77
Large 7.5/7.4 1.03(0.88–1.21) .68
Broadly defined NPs (N = 2,569) All 46.2/46.6 0.97(0.81–1.16) .75
Medium 40.7/41.8 0.96(0.80–1.15) .65
Large 9.4/8.7 1.06(0.78–1.44) .73
Narrowly defined NPs (N = 689) All 50.7/44.0 1.36(0.95–1.94) .092
Medium 43.5/38.8 1.24(0.86–1.78) .26
Large 10.1/9.5 1.18(0.62–2.22) .61
Anxiety/depression (N = 383) All 49.6/43.3 1.21(0.77–1.91) .41
Medium 41.2/40.1 0.96(0.61–1.52) .87
Large 12.4/3.8 3.75(1.45–9.68) .0064
Anxiety/depression, adjusting for NPs (N = 383) All 49.6/43.3 1.20(0.76–1.92) .43
Medium 41.2/40.1 0.93(0.58–1.48) .76
Large 12.4/3.8 4.28(1.71–10.73) .0019
CI, 95% confidence interval; CNV, copy number variant; NPs, neurodevelopmental problems.
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Several secondary analyses helped to characterize the role of
CNVs in NPs and to pinpoint the categories of CNVs most relevant to
NPs. Our results showed that narrowly defined NPs (i.e., real-life clini-
cal diagnoses independent of the study design) have specific associa-
tions with particularly large (>500 kb) CNVs, especially deletions and
CNVs in regions previously implicated in other neuropsychiatric disor-
ders and evolutionarily constrained, critical biological processes.
Moreover, large deletions were enriched in narrowly defined NPs
compared to broadly defined NPs. Conversely, medium-sized
(100–500 kb) deletions and large duplications were associated with
broadly defined NPs. In addition to large CNVs that were likely to be
relevant to NPs, large CNVs not affecting these regions were also rel-
evant to broadly defined NPs. Thus, the evidence suggests that espe-
cially highly deleterious CNVs are associated with clinical diagnoses of
NPs, whereas arguably somewhat less deleterious CNVs are associ-
ated with NPs defined more broadly in the population. This effect
may be driven by larger CNVs having a more severe outcome as they
disrupt more genes than medium-sized CNVs, as well as a possible dif-
ferential phenotypic impact of duplicated compared to deleted genetic
material.
This study suggests that rare genetic variants related to clinically
diagnosed disorders are also relevant to more broadly defined prob-
lems in the general population, consistent with previous twin and
common variant studies (Martin et al., 2017). When examining NPs as
a continuous distribution of symptoms, we saw a similar pattern of
associations to when NPs were defined dichotomously, with attenu-
ated, albeit largely consistent, effects when clinically diagnosed indi-
viduals were excluded (possibly as a result of reduced power). These
results support the idea that neurodevelopmental disorders reflect the
quantitative extreme of genetic factors operating dimensionally
among individuals in the general population. These results are also
consistent with studies adopting a genetics-first approach, which have
demonstrated that individuals with rare syndromes that are defined
by specific rare CNVs (e.g., 22q11.2 deletion syndrome or Williams
syndrome) show elevated levels of NPs, that do not always meet clini-
cal diagnostic thresholds (Scerif & Baker, 2015; Tang, Antshel,
Fremont, & Kates, 2015).
Multiple NPs were deliberately combined in this study because of
the high comorbidity and shared genetic risk between different disor-
ders (Lichtenstein, Carlström, Råstam, Gillberg, & Anckarsäter, 2010;
Thapar et al., 2017). It has been suggested that a broad and heritable
general psychopathology factor underlies NPs (Neumann et al., 2016;
Pettersson, Larsson, & Lichtenstein, 2015). Our current results lend
support to this idea by demonstrating that CNVs are to a large degree
nonspecific, affecting multiple related neurodevelopmental outcomes
in children from the general population. Although the analyses of spe-
cific NPs suggested that CNVs were most strongly associated with
ADHD, motor problems and learning difficulties, these outcomes were
in fact the most common ones in the sample (see Table 1); the esti-
mated confidence intervals overlapped to a large degree for the differ-
ent NPs and it is likely that these comparisons were affected by
decreased power for ASD and tic problems. Thus, our results lend fur-
ther evidence for pleiotropy of genetic risks impacting on multiple
outcomes.
The second aim of our study was to determine whether CNVs
showed sex-specific associations that could elucidate the excessive
male bias seen in NPs. In contrast to the previous clinical studies
which reported an increased burden of large, rare CNVs in females
with diagnosed ASD and developmental delay (Gilman et al., 2011;
Jacquemont et al., 2014; Levy et al., 2011), our results showed no
differences in CNV presence in males and females with NPs. This
inconsistency may be because of ascertainment and measurement
differences. The previous studies were clinically ascertained samples
of children meeting research-based diagnostic criteria for NPs,
whereas the current dataset is a childhood population cohort study,
with NPs defined using either a lifetime clinician's diagnosis (that is
independent of study recruitment) or a broad study screening mea-
sure. Females diagnosed with ASD in clinical cohorts may be more
severely affected and have more comorbid problems than affected
males, which could also explain the discrepancy between previous
studies and our results in this population sample (Gilman et al., 2011;
Jacquemont et al., 2014; Levy et al., 2011).
Interestingly, we detected more large, rare CNVs in females with
ICD diagnoses of anxiety or depression than in diagnosed males. This
result could suggest that large, rare CNVs manifest differently in males
and females. Adjusting for comorbid NPs (by including NP traits as a
covariate) appeared to strengthen the association. This indicates that
comorbid NPs in females with anxiety or depression do not explain
the observed results. One interpretation is that large, rare CNVs may
be more likely to be associated with anxiety or depression diagnoses
in females. A complementary interpretation is that males with such
CNVs may be less likely to be diagnosed with anxiety or depression;
although the rate of large CNVs was similar by sex in the whole sam-
ple (females: 7.5%; males: 7.4%), in the individuals with diagnosed
anxiety or depression, females had an increased rate (12.4%) whereas
males had a decreased rate (3.8%) of large CNVs. In contrast to the
male bias seen in NPs, epidemiological studies show a female bias
toward diagnoses of anxiety and depression (Craske et al., 2017;
Weissman et al., 1996). Given that the anxiety/depression diagnoses
in this study were obtained from the study-independent Swedish NPR
and individuals were not comprehensively screened for these clinical
diagnoses, our results hint that this prevalence difference may be in
part as a result of sex-specific referral or diagnostic biases, where
female CNV carriers who manifest psychopathology and are referred
for clinical assessment may be more likely to receive diagnoses of anx-
iety or depression rather than NPs, which are more common in males.
A complementary finding was recently reported in the same dataset,
whereby common risk alleles for ADHD are also enriched in females
diagnosed with anxiety or depression as compared to affected males
(Martin, Taylor, et al., 2018). However, the sample size of diagnosed
individuals is limited in the current dataset and larger studies are
needed to replicate and further interpret this novel finding.
The strengths of this study include the use of a large homogenous
population sample with genome-wide data as well as multiple assess-
ments of NPs (based on study screening using parental questionnaires
and study-independent “real-life” clinician's diagnoses). However, as
this was a general population cohort, the proportion of individuals
with clinical diagnoses was small, which of course constrains the
power of the analyses. In particular, we were limited by sample size
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for analyzing specific NPs and thus broadly and narrowly defined
problems were grouped to maximize power. As such, the classes of
CNVs associated with specific NPs (e.g., medium deletions and large
duplications associated with ADHD) may not generalize to associa-
tions only seen in clinically diagnosed disorders (Girirajan et al., 2011;
Huang et al., 2017; Mosca et al., 2016; Sanders et al., 2015; Williams
et al., 2012). The power was further limited for stratifying rare CNVs
by size, type, and relevance to NPs, so we are unable to draw conclu-
sions about the specific loci (and for the sex-specific analyses even
the category of CNVs) that may be driving observed associations.
Another limitation is that certain types of CNVs and other structural
variants (e.g., individuals with possible aneuploidies) were excluded
from the study during QC, which may have affected the generalizabil-
ity of our results to a broader class of rare structural variation in the
general population.
In conclusion, this study demonstrates that rare CNVs not only
impact on clinically recognized neurodevelopmental disorders in chil-
dren but also on more broadly defined subthreshold and continuously
defined NPs, which has not been reported previously in a nonclinical
childhood population sample. Future studies using large genome-wide
datasets are needed to further determine the role of specific rare
genomic loci in NPs and other psychiatric phenotypes in the general
population. Our results add to studies of CNVs in adult populations
(Kendall et al., 2016; Männik et al., 2015; Stefansson et al., 2014) and
one recent childhood population study (Guyatt et al., 2018), demon-
strating that population datasets with information on broad psychiat-
ric problems will be an important addition to case–control studies in
characterizing the role of rare variation in relation to neuropsychiatric
phenotypes. Our study also finds evidence of a novel association
between large, rare CNVs with anxiety and depression in females
compared to males. This points to a possible role of sex-specific mani-
festation of CNVs that would benefit from further study.
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